These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35106962)

  • 1. Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study.
    Boissel N; Chevallier P; Doronin V; Griskevicius L; Maschan A; McCloskey J; Rambaldi A; Rossi G; Sokolov A; Wartiovaara-Kautto U; Oprea C; Abbadessa G; Gosselin A; Macé S; Thomas X
    Cancer Med; 2022 Mar; 11(5):1292-1298. PubMed ID: 35106962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
    Sunami K; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Kaneko H; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Takahashi K; Tada K; Macé S; Guillemin-Paveau H; Iida S
    Cancer Sci; 2020 Dec; 111(12):4526-4539. PubMed ID: 32975869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia.
    Wang A; Song Z; Zheng G; Nicolazzi C; Fromm JR; Shehu E; Srinivasan S; Chen X; Zhu C; Blondel MC; Adrian FJ
    Mol Cancer Ther; 2021 Oct; 20(10):1916-1925. PubMed ID: 34376579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
    Carlo-Stella C; Zinzani PL; Sureda A; Araújo L; Casasnovas O; Carpio C; Yeh SP; Bouabdallah K; Cartron G; Kim WS; Cordoba R; Koh Y; Re A; Alves D; Chamuleau M; Le Gouill S; López-Guillermo A; Moreira I; van der Poel MWM; Abbadessa G; Meng R; Ji R; Lépine L; Saleem R; Ribrag V
    Hematol Oncol; 2023 Feb; 41(1):108-119. PubMed ID: 36251503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Borthakur G; Martinelli G; Raffoux E; Chevallier P; Chromik J; Lithio A; Smith CL; Yuen E; Oakley GJ; Benhadji KA; DeAngelo DJ
    Cancer; 2021 Feb; 127(3):372-380. PubMed ID: 33107983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma.
    Martin T; Strickland S; Glenn M; Charpentier E; Guillemin H; Hsu K; Mikhael J
    Blood Cancer J; 2019 Mar; 9(4):41. PubMed ID: 30926770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
    Huang YH; Wan CL; Dai HP; Xue SL
    Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
    Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
    Simonelli M; Garralda E; Eskens F; Gil-Martin M; Yen CJ; Obermannova R; Chao Y; Lonardi S; Melichar B; Moreno V; Yu ML; Bongiovanni A; Calvo E; Rottey S; Machiels JP; Gonzalez-Martin A; Paz-Ares L; Chang CL; Mason W; Lin CC; Reardon DA; Vieito M; Santoro A; Meng R; Abbadessa G; Menas F; Lee H; Liu Q; Combeau C; Ternes N; Ziti-Ljajic S; Massard C
    ESMO Open; 2022 Oct; 7(5):100562. PubMed ID: 35987165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
    Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults.
    Temple WC; Mueller S; Hermiston ML; Burkhardt B
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101449. PubMed ID: 36907639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.